When to make an appointment for joint soreness

When to make a routine appointment

Which changes deserve a regular doctor’s visit? Ongoing swelling, catching, weakness, or trouble standing should be examined. Stairs, sleep, dressing, or walking may have become harder. Those daily limits tell the doctor how much the soreness affects you.

The doctor will ask how the trouble began and examine the joint. Mention an old injury, even when it happened long ago. An earlier X-ray or diagnosis gives useful history, but your joint may have changed since then. The current exam still matters.

A visit is also useful when you aren’t sure which movement is safe. You can ask about exercise, physical therapy, a brace, or medicine for the sore joint. If those choices haven’t helped, ask what else the exam supports. There’s no need to decide before hearing the answer.

When to seek help sooner

When should you go to an emergency room? Go now when a joint is very hot and badly swollen and you also have a fever. After a fall, sudden trouble standing, new numbness, or great weakness belongs in emergency care. Losing control of the bladder or bowel is another reason to go. Please don’t wait for a joint clinic appointment.

Call your doctor or the office that performed the care if soreness worsens afterward. Fast worsening, weight loss you can’t explain, or strong pain at night also deserves a prompt call. Tell them exactly which sign appeared and when it began. They can say whether you need their office, an urgent clinic, or an emergency room.

Sources

1. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

4. A CDC-led national public health investigation identified culture-confirmed bacterial infections in 20 patients (median age 63) across 8 US states who received umbilical cord blood-derived products marketed as stem cell treatment for pain, osteoarthritis, rheumatoid arthritis and injury. ALL BUT ONE REQUIRED HOSPITALISATION. Of unopened, undistributed product vials sampled, 65% (22 of 34) were contaminated with at least one of 16 bacterial species, mostly enteric; whole-genome sequencing linked an Arizona patient isolate to product administered in Florida.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies.. JAMA network open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

5. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.